Mural Oncology is a new, independent publicly traded company with $275M in cash1, providing runway into 4Q 2025. Highly experienced senior leadership team with deep immuno-oncology experience Nemvaleukin is an intrinsically active, stable fusion protein which does not degrade into native-IL-2 and is designed to selectively bind to the intermediate-affinity IL-2 receptor, enabling a potentially enhanced therapeutic window Mural Oncology - Building a Novel Engineered Cytokine Company Nemvaleukin has generated compelling clinical data to date, with durable responses2 in monotherapy and in PD-1 combination across a range of tumor types. ARTISTRY-6 and ARTISTRY-7 readouts both expected in 1H 20253 Portfolio of novel, investigational cytokines engineered to optimize the “known knowns” of native interleukins (IL) – retain their high potency while potentially overcoming their low tolerability IL-18 and IL-12 programs in development with potentially differentiated therapeutic properties and leveraging advanced protein engineering capabilities. Candidate nominations expected in 2024 1 2 4 3 Mural Oncology Abbrev.: IL-2: interleukin-2: IL-12: interleukin-12; IL-18: interleukin-18 5 Cash balance as of Nov 15, 2023 Durable response defined as a response with a duration that exceeds the response generally observed with standard of care treatment; in the context of high unmet disease states such as mucosal melanoma and platinum-resistant ovarian cancer (“PROC”), a response that exceeds six months is considered durable Subject to patient enrollment
Company profile
Ticker
MURA
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Mural Oncology Ltd
SEC CIK
Subsidiaries
Mural Oncology, Inc. • Biopharmaceuticals, Inc. • Mural Oncology Securities Corporation ...
MURA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
12 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Apr 24
DEF 14A
Definitive proxy
12 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
26 Mar 24
S-8
Registration of securities for employees
16 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
10-Q
2023 Q3
Quarterly report
14 Dec 23
8-K
Entry into a Material Definitive Agreement
15 Nov 23
S-8
Registration of securities for employees
13 Nov 23
Latest ownership filings
4/A
Caroline Loew
11 Apr 24
SC 13G/A
WESTFIELD CAPITAL MANAGEMENT CO LP
4 Apr 24
4
Caroline Loew
4 Mar 24
4
Maiken Keson-Brookes
4 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
BlackRock Inc.
2 Feb 24
SC 13G
WESTFIELD CAPITAL MANAGEMENT CO LP
10 Jan 24
4
Vicki L Goodman
18 Dec 23
4
Francis M Cuss
18 Dec 23
Financial summary
Quarter (USD) | Sep 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Caroline Loew | Ordinary Shares | Grant | Acquire A | No | No | 0 | 48,475 | 0.00 | 252,922 |
1 Mar 24 | Caroline Loew | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 5.39 | 90,025 | 485.23 k | 90,025 |
1 Mar 24 | Maiken Keson-Brookes | Ordinary Shares | Grant | Acquire A | No | No | 0 | 16,800 | 0.00 | 46,007 |
1 Mar 24 | Maiken Keson-Brookes | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 5.39 | 31,200 | 168.17 k | 31,200 |
14 Dec 23 | Caroline Loew | Ordinary Shares | Grant | Acquire A | No | No | 0 | 37,171 | 0.00 | 37,171 |
14 Dec 23 | Caroline Loew | Ordinary Shares | Grant | Acquire A | No | No | 0 | 167,276 | 0.00 | 167,276 |
14 Dec 23 | Caroline Loew | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 3.61 | 379,690 | 1.37 mm | 379,690 |
14 Dec 23 | Vicki L Goodman | Ordinary Shares | Grant | Acquire A | No | No | 0 | 73,018 | 0.00 | 73,018 |
14 Dec 23 | Vicki L Goodman | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 3.61 | 135,604 | 489.53 k | 135,604 |
14 Dec 23 | Cuss Francis M | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 3.61 | 15,021 | 54.23 k | 15,021 |
News
Mural Oncology Presents Preclinical Data For IL-18 and IL-12 Programs At 2024 American Association For Cancer Research Annual Meeting
9 Apr 24
Morgan Stanley Initiates Coverage On Mural Oncology with Overweight Rating, Announces Price Target of $13
4 Apr 24
Mural Oncology Q4 EPS $(3.57) Down From $(2.91) YoY, Cash Balance of $270.9M
26 Mar 24
Press releases
Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
24 Apr 24
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
9 Apr 24
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Apr 24
Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
5 Mar 24
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Mar 24